ADMA Biologics (NASDAQ:ADMA) Announces Quarterly Earnings Results

ADMA Biologics (NASDAQ:ADMA) issued its quarterly earnings data on Wednesday. The biotechnology company reported $0.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.20 by $0.03, FiscalAI reports. ADMA Biologics had a net margin of 35.14% and a return on equity of 42.89%. The firm had revenue of $141.10 million during the quarter, compared to the consensus estimate of $138.11 million. During the same period last year, the business posted $0.15 earnings per share. The business’s revenue for the quarter was up 5.1% compared to the same quarter last year.

Here are the key takeaways from ADMA Biologics’ conference call:

• ASCENIV drove growth: Revenue rose 31% year over year to $124.7 million, with management citing broader physician adoption, new patient starts, and continued pull-through. The company said primary immunodeficiency remains the main growth driver, while uptake in secondary immunodeficiency has been more moderate.
• Profitability and outlook improved: Gross margin reached 71%, and adjusted EBITDA grew 32% year over year to $77.3 million. ADMA maintained its 2026 revenue outlook of at least $530 million while raising minimum adjusted EBITDA guidance to $275 million and adjusted net income guidance to $180 million.
• BIVIGAM remained under pressure: Revenue fell to $15.4 million from $19.4 million in the second quarter and $23.8 million a year earlier, amid pricing and channel competition. Management noted signs of utilization stabilization entering the fourth quarter but said discounting pressures persist.
• Share repurchases continued at scale: ADMA repurchased $181.4 million of stock in the first nine months, buying back 16.5 million shares, or about 6.3% of year-end 2025 shares outstanding. The company reiterated its target of at least $200 million in repurchases for 2026.
• SG-001 advanced, but timing remains uncertain: The FDA provided constructive pre-IND feedback on the candidate’s proposed clinical strategy and assay, and ADMA plans to incorporate recommendations into its IND preparations. Management did not provide a filing timeline and expects higher fourth-quarter R&D spending as it produces conformance lots.

ADMA Biologics Price Performance

Shares of ADMA stock traded down $0.20 during trading on Friday, hitting $13.01. The company had a trading volume of 2,476,296 shares, compared to its average volume of 4,171,576. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.81 and a current ratio of 6.97. The firm has a market capitalization of $2.91 billion, a P/E ratio of 16.93 and a beta of 0.65. The stock’s 50-day moving average price is $10.14 and its 200 day moving average price is $10.91. ADMA Biologics has a one year low of $7.21 and a one year high of $20.46.

Key Headlines Impacting ADMA Biologics

Here are the key news stories impacting ADMA Biologics this week:

• Positive Sentiment: ADMA’s third-quarter revenue was $141.1 million, above estimates of about $138.1 million, while adjusted EPS of $0.23 topped consensus of $0.20. Net income rose 37% year over year, and gross margin expanded to 71%. Results were driven by ASCENIV, whose revenue increased 31% to $124.7 million. ADMA third-quarter results and business update
• Positive Sentiment: The company reiterated its 2026 revenue outlook of at least $530 million and raised its minimum adjusted EBITDA outlook to $275 million, citing accelerating ASCENIV demand. This signals confidence in profitability and growth. ADMA guidance update
• Positive Sentiment: Canaccord Genuity maintained its Buy rating. Separately, ADMA moved above its 20-day and 200-day moving averages, which technical analysts view as signals of short- and longer-term bullish momentum. Canaccord rating 20-day moving average report
• Neutral Sentiment: Cantor Fitzgerald raised its price target to $13 from $12 but kept a Neutral rating, indicating a more cautious view than Canaccord’s Buy stance. Cantor Fitzgerald rating and target
• Negative Sentiment: ASCENIV’s strength offset weaker Bivigam sales, a reminder that performance remains reliant on growth from its leading product. Product sales report

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on ADMA shares. Cantor Fitzgerald increased their target price on ADMA Biologics from $12.00 to $13.00 and gave the stock a “neutral” rating in a research note on Thursday. Mizuho set a $18.00 price target on ADMA Biologics in a research note on Thursday. Zacks Research upgraded ADMA Biologics from a “strong sell” rating to a “hold” rating in a research report on Wednesday, September 2nd. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of ADMA Biologics in a research report on Monday, September 14th. Three research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, ADMA Biologics has a consensus rating of “Moderate Buy” and an average price target of $17.50.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company focused on developing, manufacturing and commercializing plasma-derived biologic products for people with compromised or weakened immune systems. The company’s activities include collecting human plasma, developing immune globulin therapies and manufacturing products for use in the prevention and treatment of certain infectious diseases.

ADMA’s portfolio includes Asceniv, an intravenous immune globulin indicated for primary humoral immunodeficiency disease, and Bivigam, an intravenous immune globulin used for the treatment of primary humoral immunodeficiency.